Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19(+) B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment–mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother
Main Authors: Qin, Jim S., Johnstone, Timothy G., Baturevych, Alex, Hause, Ronald J., Ragan, Seamus P., Clouser, Christopher R., Jones, Jon C., Ponce, Rafael, Krejsa, Cecile M., Salmon, Ruth A., Ports, Michael O.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
Basic Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7144752/
https://ncbi.nlm.nih.gov/pubmed/31899702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados